Adage Capital Partners’s Taysha Gene Therapies TSHA Stock Holding History

Adage Capital Partners’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.77M	Buy	+553,000	New	+$3.27M	0.01%	835
2026 Q1	–	Sell	-1,328,000	Closed	-$7.3M	–	1076
2025 Q4	$7.3M	Sell	1,328,000 -2,000,000	-60%	-$9.71M	0.01%	718
2025 Q3	$10.9M	Sell	3,328,000 -1,511,000	-31%	-$4.28M	0.02%	611
2025 Q2	$11.2M	Buy	+4,839,000	New	+$10.5M	0.02%	592
2025 Q1	–	Sell	-5,000,000	Closed	-$8.65M	–	945
2024 Q4	$8.65M	Buy	+5,000,000	New	+$10.4M	0.02%	642
2024 Q2	–	Sell	-220,000	Closed	-$631K	–	939
2024 Q1	$631K	Sell	220,000 -200,000	-48%	-$417K	﹤0.01%	803
2023 Q4	$743K	Sell	420,000 -1,080,000	-72%	-$2.15M	﹤0.01%	771
2023 Q3	$4.74M	Buy	+1,500,000	New	+$2.8M	0.01%	670

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners's TSHA Position: Q2 2026 in Review

Adage Capital Partners opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 553,000 shares worth $3.77M. The stake represents 0.01% of the portfolio and ranks #835 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in TSHA as recently as Q4 2025.

Adage Capital Partners first reported a position in TSHA in Q3 2023 and has held it in 8 quarters since. The position peaked at $11.2M in Q2 2025. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Adage Capital Partners held 553,000 shares of Taysha Gene Therapies worth $3.77M as of Q2 2026.
Taysha Gene Therapies was a new Adage Capital Partners position in Q2 2026.
Taysha Gene Therapies made up 0.01% of Adage Capital Partners's portfolio in Q2 2026, its #835 holding.
Adage Capital Partners first reported a position in Taysha Gene Therapies in Q3 2023 and has held it in 8 quarters since.
Adage Capital Partners's Taysha Gene Therapies position peaked at $11.2M in Q2 2025.
209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.